The news: A gene-edited pig’s heart has been transplanted into a human being for the first time. David Bennett Sr., a man with terminal heart disease, received the genetically modified heart during an eight-hour operation on Friday January 7 at the University of Maryland Medical Center, which issued a statement last night. The operation was a last-ditch effort on behalf of Bennett, 57, who had been deemed ineligible for a conventional heart transplant. He had been in the hospital for more than six weeks before the procedure with life-threatening arrhythmia. “It was either die or do this transplant,” he said in the press statement. “I want to live. I know it’s a shot in the dark, but it’s my last choice.”
The technique: Ten genes in the donor pig were altered before the transplant could take place. Three of these genes cause human bodies to reject pig organs, so these were knocked out. Six genes were inserted to help control immune acceptance of the pig heart, and one additional gene was knocked out to stop excessive growth of the pig heart tissue.
The Maryland team also used an experimental drug to suppress the immune system and prevent rejection, and a new machine that pushed fluid through the tissue to make sure the pig’s heart remained viable until the procedure. The FDA gave emergency go-ahead for the procedure on New Year’s Eve, according to the New York Times.
What’s next: The demand for organs is vast, with nearly 107,000 people on the US transplant waiting list; 17 of them die every day, according to the Health Resources and Services Administration, a federal agency.
Early results look promising for Bennett, who is expected to come off the heart-lung bypass machine he’d been relying on to keep him alive today (January 11). He will be very closely monitored over the coming days and weeks for any signs of rejection or infection.
New frontier: While xenotransplantation, the process of transplanting animal organs or tissues into humans, has a long and often unsuccessful history, new gene-editing technologies are making it more viable. The gene-edited pig in last week’s operation was supplied by Revivicor, one of several biotech companies working to develop pig organs to transplant into humans.
Revivicor was also behind a successful transplantation of a pig’s kidney into a human patient last October, which was a major milestone in proving the viability of its techniques. As well as Revivicor, Harvard scientist George Church cofounded a company, eGensisis, that is working on using CRISPR gene editing to make animal organs viable for human transplant, although his ambitious proposed time scale has fallen off track.
Correction: We updated the first line to make it clear this was the first gene-edited heart.
Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging
The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.
Anti-aging drugs are being tested as a way to treat covid
Drugs that rejuvenate our immune systems and make us biologically younger could help protect us from the disease’s worst effects.
Why China is still obsessed with disinfecting everything
Most public health bodies dealing with covid have long since moved on from the idea of surface transmission. China’s didn’t—and that helps it control the narrative about the disease’s origins and danger.
A new storage technique could vastly expand the number of livers available for transplant
It allows donor livers to be held for days—significantly longer than the standard now–and even treated if they are damaged.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.